Position in BIAF
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$0
+$0 QoQ
Shares Held
17,162
-13.5% QoQ
Ownership
3.18%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
15 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BIAF Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $1,695,016,013 across 33 Diagnostics & Research names. BIAF ranks #32 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
574,992 | $288,277,988 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
1,193,601 | $270,696,770 | |
| 3 | GH |
Guardant Health, Inc.
|
1,449,534 | $217,473,585 | |
| 4 | DHR |
Danaher Corp /De/
|
943,694 | $179,754,833 | |
| 5 | RVTY |
Revvity, Inc.
|
1,457,335 | $162,143,091 | |
| 6 | A |
Agilent Technologies, Inc.
|
1,101,501 | $146,312,377 | |
| 7 | NTRA |
Natera, Inc.
|
265,607 | $72,099,020 | |
| 8 | WGS |
GeneDx Holdings Corp.
|
865,462 | $59,413,965 |
All Filings in BIAF
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2025-12-31 | $13,724 | 11,631 | Shares | Defined | 2026-02-17 | |
| 2024-12-31 | $12,070 | 13,264 | Shares | Defined | 2025-02-14 | |
| 2022-09-30 | $59,896 | 20,583 | Shares | Defined | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||